Naba Alsaha Medical Services Company
TADAWUL:9546.SR
93 (SAR) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SAR.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 100.512 | 50.256 | 81.841 | 40.92 | 66.786 | 33.393 | 62.898 | 31.449 | 61.119 | 30.56 | 56.562 | 28.281 |
| Cost of Revenue
| 60.376 | 31.184 | 48.207 | 24.103 | 42.481 | 22.12 | 35.564 | 17.782 | 37.491 | 19.455 | 33.408 | 16.704 |
| Gross Profit
| 40.135 | 19.072 | 33.634 | 16.817 | 24.305 | 11.273 | 27.335 | 13.667 | 23.629 | 11.105 | 23.155 | 11.577 |
| Gross Profit Ratio
| 0.399 | 0.38 | 0.411 | 0.411 | 0.364 | 0.338 | 0.435 | 0.435 | 0.387 | 0.363 | 0.409 | 0.409 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 5.798 | 5.798 | 7.488 | 7.488 | 4.8 | 4.8 | 5.845 | 5.845 | 3.292 | 3.292 | 4.49 | 4.49 |
| Selling & Marketing Expenses
| 0.547 | 0.547 | 7.488 | 0 | 0.249 | 0.249 | 5.845 | 0 | 0.626 | 0.626 | 4.49 | 0 |
| SG&A
| 15.827 | 6.48 | 14.976 | 7.488 | 11.639 | 4.193 | 11.69 | 5.845 | 10.831 | 4.282 | 8.98 | 4.49 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 15.827 | 6.036 | 14.976 | 2.318 | 11.639 | 4.851 | 11.69 | 5.516 | 10.831 | 4.742 | 8.98 | 4.051 |
| Operating Income
| 24.309 | 12.592 | 18.658 | 9.329 | 12.666 | 7.08 | 15.645 | 7.823 | 12.798 | 6.823 | 14.174 | 7.087 |
| Operating Income Ratio
| 0.242 | 0.251 | 0.228 | 0.228 | 0.19 | 0.212 | 0.249 | 0.249 | 0.209 | 0.223 | 0.251 | 0.251 |
| Total Other Income Expenses Net
| 2.043 | 0.38 | 10.568 | 5.13 | 0.198 | -0.712 | 0.553 | 0.277 | -0.19 | -0.519 | 0.746 | 0.373 |
| Income Before Tax
| 26.352 | 12.972 | 29.226 | 14.459 | 12.864 | 6.368 | 16.198 | 8.099 | 12.608 | 6.304 | 14.921 | 7.46 |
| Income Before Tax Ratio
| 0.262 | 0.258 | 0.357 | 0.353 | 0.193 | 0.191 | 0.258 | 0.258 | 0.206 | 0.206 | 0.264 | 0.264 |
| Income Tax Expense
| 1.331 | 0.665 | 1.149 | 0.575 | 1.206 | 0.603 | 0.805 | 0.403 | 1.012 | 0.506 | 0.689 | 0.344 |
| Net Income
| 24.613 | 12.307 | 27.769 | 13.885 | 11.53 | 5.765 | 15.393 | 7.696 | 11.595 | 5.798 | 14.232 | 7.116 |
| Net Income Ratio
| 0.245 | 0.245 | 0.339 | 0.339 | 0.173 | 0.173 | 0.245 | 0.245 | 0.19 | 0.19 | 0.252 | 0.252 |
| EPS
| 2.34 | 1.17 | 2.64 | 1.32 | 1.1 | 0.55 | 1.47 | 0.73 | 1.1 | 0.55 | 1.36 | 0.68 |
| EPS Diluted
| 2.34 | 1.17 | 2.64 | 1.32 | 1.1 | 0.55 | 1.47 | 0.73 | 1.1 | 0.55 | 1.36 | 0.68 |
| EBITDA
| 28.998 | 14.489 | 23.463 | 11.273 | 16.131 | 8.4 | 18.945 | 9.102 | 16.023 | 8.069 | 17.071 | 8.165 |
| EBITDA Ratio
| 0.289 | 0.288 | 0.287 | 0.275 | 0.242 | 0.252 | 0.301 | 0.289 | 0.262 | 0.264 | 0.302 | 0.289 |